Goldman Sachs Group, Inc. September "Conviction List" update: U.S. stocks include Vertex Pharmaceuticals Incorporated (VRTX.US) while European stocks recommend Rhein, Adyen, and Talanks.

As autumn approaches, Goldman Sachs Group, Inc. has updated its Conviction List for the U.S. and European markets, indicating the current most favored stock directions for investors. In this adjustment, the U.S. list adds one large biotech stock, while the European list welcomes three newcomers. U.S. List: Added Vertex Pharmaceuticals Incorporated, removed Interactive Brokers Group, Inc. Class A In the U.S. market, Goldman Sachs Group, Inc. has included Vertex Pharmaceuticals Incorporated (VRTX.US) in its Conviction List, while removing Interactive Brokers Group, Inc. Class A (IBKR.US). The adjusted list retains 23 stocks. Analyst Salveen Richter believes that large biotech company Vertex Pharmaceuticals Incorporated has a solid foundation for long-term growth, as it is seizing up to five potential opportunities worth billions of dollars, covering cystic fibrosis, pain treatment, nephrology, and hematology. Additionally, the proposed acquisition of Crinetics (CRNX.US) will further strengthen its fifth pillar in endocrinology. Other stocks on the U.S. market list include Estee Lauder Companies Inc. Class A (EL.US), Wells Fargo & Company (WFC.US), UnitedHealth Group Incorporated (UNH.US), Delta Air Lines, Inc. (DAL.US), ConocoPhillips (COP.US), Microsoft Corporation (MSFT.US), and Block (XYZ.US). European List: Added RWE, Adyen, and Talanx, removed four stocks In the European market, Goldman Sachs Group, Inc. has added German energy giant RWE, Dutch payment company Adyen, and German insurance company Talanx, while removing Enel, Wise, Hannover Re, and Zalando. Analyst Alberto Gandolfi noted that RWE, after acquiring a majority stake in Amprion, is transitioning from an electricity producer to a vertically integrated energy giant, and its stock is expected to undergo a valuation reassessment. Gandolfis forecast for earnings per share in 2031 is about 25% higher than the companys guidance and market consensus, expecting an annual earnings growth rate of around 17% by 2031, and raising the target price by 6%, maintaining a buy rating with a potential upside of 27%. Goldman Sachs Group, Inc. believes that Adyens technology stack remains a key differentiating advantage, with its EBITDA forecasts for 2027 to 2029 exceeding market consensus by 4% to 6%. The firm also stated that Talanxs international retail business is an underestimated growth engine.